HCW Biologics, Partners Identify TGF-β Trap, IL-15 Fusion As Novel Moiety With Potential Applications Against Diseased Cell, Viral Infections
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune
HCW Biologics found a new way to combine two medicines that might help fight diseases and infections. Scientists look for early discoveries like this all the time, but it takes years of testing before anyone knows if it really works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.